Ecklonia cava polyphenols (ECPs) show promise in reducing neuronal damage caused by rotenone in Parkinson’s disease (PD) by activating the Nrf2-ARE pathway, highlighting their potential as a neuroprotective treatment.
TRYP THERAPEUTICS OBTAINS INTERIM ORDER FOR PLAN OF ARRANGEMENT AND PROVIDES DETAILS OF SHAREHOLDER MEETING – Biotech Investments
, 02/08/2024 / 16:00, EST/EDT – EQS Newswire – Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange,